Expertise in
3
conditions

Jihong S. Liu

Tianhe Road, 
Guangzhou, CN 
Expertise in
3
conditions
Tianhe Road, 
Guangzhou, CN 
OverviewLocationsClinical Research

Overview

Jihong Liu practices in Guangzhou, China. Liu is highly rated in 3 conditions, according to our data. Their top areas of expertise are Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Lymphadenectomy, and Hysterectomy.

Their clinical research consists of co-authoring 107 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Tianhe Road, Guangzhou, 510630, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
A Phase III Study to Evaluate the Efficacy and Safety of IMP4297 Following 1st Line Chemotherapy in the Monotherapy Maintenance Treatment of Subjects With Ovarian Cancer
A Phase III Study to Evaluate the Efficacy and Safety of IMP4297 Following 1st Line Chemotherapy in the Monotherapy Maintenance Treatment of Subjects With Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2025
Intervention Type: Drug
Study Drug: IMP4927
Study Phase: Phase 3
A Randomized，Double-blind，Controlled，Multi-center Phase III Clinical Study Evaluating SHR-1701 or Placebo Plus Chemotherapy With or Without BP102 (Bevacizumab) as First-Line Treatment in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Randomized，Double-blind，Controlled，Multi-center Phase III Clinical Study Evaluating SHR-1701 or Placebo Plus Chemotherapy With or Without BP102 (Bevacizumab) as First-Line Treatment in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
Enrollment Status: Terminated
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drugs: SHR-1701, Paclitaxel, Cisplatin, Carboplatin, BP102
Study Phase: Phase 3
A Study of QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
A Study of QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
Enrollment Status: Terminated
Publish Date: January 12, 2024
Intervention Type: Drug
Study Drugs: QL1604, Paclitaxel, Cisplatin, Carboplatin
Study Phase: Phase 2/Phase 3
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Bintrafusp Alfa
Study Phase: Phase 2
View 4 Less Clinical Trials

107 Total Publications

Exosomal microRNA biomarkers in ovarian cancer detection: systematic review and meta-analysis.
Exosomal microRNA biomarkers in ovarian cancer detection: systematic review and meta-analysis.
Journal: Clinica chimica acta; international journal of clinical chemistry
Published: November 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Liu's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile